<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03071926</url>
  </required_header>
  <id_info>
    <org_study_id>Fudan BR2017-22</org_study_id>
    <nct_id>NCT03071926</nct_id>
  </id_info>
  <brief_title>Metronomic PLD in Patients With Primary Endocrine Resistant ABC</brief_title>
  <official_title>Efficacy and Safety of Metronomic Pegylated Liposomal Doxorubicin in Patients With Primary Endocrine Resistant Advanced Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Metronomic PLD in Patients with Primary Endocrine Resistant ABC
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Efficacy and Safety of Metronomic Pegylated Liposomal Doxorubicin in Patients with Primary
      Endocrine Resistant Advanced Breast Cancer
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months</time_frame>
    <description>Progression Free Survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number and grade of treatment-related cardiotoxicity as assessed by CTCAE v4.0</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months</time_frame>
    <description>monitoring LVEF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months</time_frame>
    <description>Overall Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CBR</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months</time_frame>
    <description>Clinical Benefit Rate</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Advanced Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Pegylated Liposomal Doxorubicin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pegylated Liposomal Doxorubicin: 20 mg, qw, first 6 weeks ,every 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated Liposomal Doxorubicin</intervention_name>
    <description>20 mg, qw, first 6 weeks ,every 8 weeks</description>
    <arm_group_label>Pegylated Liposomal Doxorubicin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Females with age between 18 and 75 years old

          2. ECOG: 0～2

          3. Life expectancy longer than 3 months

          4. Histological proven unresectable recurrent or metastatic HR positive/HER2 negative
             breast cancer

          5. Primary endocrine resistance is defined as: a relapse while on the first 2 years of
             adjuvant ET, or PD within first 6 months of first-line ET for MBC, while on ET

          6. At least one measurable disease according to RECIST 1.1(except for bone metastasis
             only)

          7. LVEF ≥ 55%

          8. No radiation therapy within 4 weeks prior to enrollment

          9. Normal function of major organs: Hb ≥ 90 g/L (no blood transfusion within 14 days)
             ;ANC ≥1.5×109 /L；PLT ≥75×109 /L；TBIL≤1. 5×ULN; ALT、 AST≤ 3×ULN（ALT、 AST≤ 5×ULN with
             hepatic metastases）; serum Cr ≤ 1×ULN

         10. Be willing to participate in the study, sign informed consent and cooperate with the
             follow-up

        Exclusion Criteria:

          1. Previous accumulated or equivalent dose of doxorubicin ≥300mg/m2

          2. Intervals of anthracycline-based adjuvant chemotherapy ≤1 year (time between
             anthracycline-based adjuvant or neoadjuvant chemotherapy and disease relapse)

          3. Patients with symptomatic central nervous system metastases. Except for patients with
             stable and asymptomatic brain metastases for at least 8 weeks and no need for
             glucocorticoids or mannitol treatment before the trial and at least one measurable
             lesion outside the brain. Radiotherapy for brain metastases should be completed at
             least 4 weeks before the registration

          4. Pregnant or lactating women and gestational age women who are unable to use effective
             contraception

          5. Treatment with investigational products within 4 weeks before the study

          6. Severe cardiopulmonary insufficiency, severe hepatic and renal dysfunction

          7. Severe or uncontrolled infection

          8. Psychiatric drugs abuse and unable to withdrawal or mental disorders

          9. Other malignancies, except for cured skin basal cell carcinoma and cervical
             intraepithelial neoplasia.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xichun Hu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xichun Hu, MD, PhD</last_name>
    <phone>64175590</phone>
    <phone_ext>85006</phone_ext>
    <email>huxicun@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhonghua Wang, MD</last_name>
    <phone>64175590</phone>
    <phone_ext>85000</phone_ext>
    <email>zhonghuawang95@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fudan University Cancer Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xichun Hu, MD,PhD</last_name>
      <phone>64175590</phone>
      <phone_ext>85006</phone_ext>
      <email>huxicun@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Zhonghua Wang, MD</last_name>
      <phone>64175590</phone>
      <phone_ext>85000</phone_ext>
      <email>zhonghuawang95@hotmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2017</study_first_submitted>
  <study_first_submitted_qc>March 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 7, 2017</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Xichun Hu</investigator_full_name>
    <investigator_title>Vice Director of department of medical oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

